Tag: Immunotherapy
Stapokibart Found to Be Superior to Placebo for Severe Chronic Rhinosinusitis With Polyps
Benefits include reduced polyp size and severity of nasal symptoms at 24 weeks
High Response to PD-1 Therapy Seen in Unresectable Desmoplastic Melanoma
Complete response rate was 37 percent, and post-hoc end point of objective response rate was 89 percent
Sustained Clinical Benefit Seen for Pembrolizumab + Axitinib in Advanced Renal Cancer
Sustained benefits seen in overall survival, progression-free survival, objective response rate with combo versus sunitinib
Patients With Leukemia Have Higher Infection Risk During Immunoglobulin Replacement Therapy
Finding seen for patients with chronic lymphocytic leukemia receiving immunoglobulin replacement therapy regularly
Rituximab Not Superior to Conventional Strategy for Eosinophilic Granulomatosis With Polyangiitis
Rituximab no better than glucocorticoids alone for inducing remission in patients with eosinophilic granulomatosis with polyangiitis
Guselkumab Efficacious for Moderately to Severely Active Crohn Disease in Adults
Both guselkumab regimens superior to placebo
Presurgical Immunotherapy Offers Long-Term Benefit in Melanoma
80 percent of adult patients with stage III/IV resectable melanoma remained event-free at four years from the start of neoadjuvant systemic treatment
Many Ineligible for Clinical Trial Could Benefit From Teclistamab for Multiple Myeloma
89 percent of 509 patients would have been ineligible for MajesTEC-1 trial; estimated median PFS was 5.8 months
Cell Therapy MDR-101 Produces Functional Immune Tolerance in Kidney Transplant Recipients
Fifteen of 20 HLA-matched living donor recipients achieved the primary end point of being immunosuppression-free for more than two years
Immune Checkpoint Inhibitor Affordability Tied to Widening Survival Disparity
Introduction of immune checkpoint inhibitors linked to widening disparity for those with private insurance versus those without insurance
